BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36336145)

  • 1. ESR1 activating mutations: From structure to clinical application.
    Grinshpun A; Chen V; Sandusky ZM; Fanning SW; Jeselsohn R
    Biochim Biophys Acta Rev Cancer; 2023 Jan; 1878(1):188830. PubMed ID: 36336145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
    Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Clinical Utility of ESR1 Mutations in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.
    Grinshpun A; Sandusky ZM; Jeselsohn R
    Hematol Oncol Clin North Am; 2023 Feb; 37(1):169-181. PubMed ID: 36435608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
    Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
    Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen Receptor Alpha and ESR1 Mutations in Breast Cancer.
    Patel JM; Jeselsohn RM
    Adv Exp Med Biol; 2022; 1390():171-194. PubMed ID: 36107319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of ESR1 Mutations in Hormone Receptor-Positive Breast Cancer.
    Reinert T; Gonçalves R; Bines J
    Curr Treat Options Oncol; 2018 Apr; 19(5):24. PubMed ID: 29666928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing.
    Ross DS; Zehir A; Brogi E; Konno F; Krystel-Whittemore M; Edelweiss M; Berger MF; Toy W; Chandarlapaty S; Razavi P; Baselga J; Wen HY
    Mod Pathol; 2019 Jan; 32(1):81-87. PubMed ID: 30158597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of ESR1 Mutations in Single Circulating Tumor Cells on Estrogen Deprivation Therapy but Not in Primary Tumors from Metastatic Luminal Breast Cancer Patients.
    Franken A; Honisch E; Reinhardt F; Meier-Stiegen F; Yang L; Jaschinski S; Esposito I; Alberter B; Polzer B; Huebner H; Fasching PA; Pancholi S; Martin LA; Ruckhaeberle E; Schochter F; Tzschaschel M; Hartkopf AD; Mueller V; Niederacher D; Fehm T; Neubauer H
    J Mol Diagn; 2020 Jan; 22(1):111-121. PubMed ID: 31669227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating
    Kumar M; Salem K; Jeffery JJ; Yan Y; Mahajan AM; Fowler AM
    J Nucl Med; 2021 Apr; 62(4):500-506. PubMed ID: 32859700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of the therapeutic strategies for ER positive breast cancer.
    Blakely B; Shin S; Jin K
    Biochem Pharmacol; 2023 Jun; 212():115552. PubMed ID: 37068524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer.
    Jeselsohn R; De Angelis C; Brown M; Schiff R
    Curr Oncol Rep; 2017 May; 19(5):35. PubMed ID: 28374222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of ESR1 variants in breast cancer.
    Heeke AL; Elliott A; Feldman R; O'Connor HF; Pohlmann PR; Lynce F; Swain SM; Nunes MR; Magee D; Oberley MJ; Swenson J; Vidal G; Isaacs C; Schwartzberg L; Korn WM; Tan AR
    Breast Cancer Res Treat; 2022 Nov; 196(2):279-289. PubMed ID: 36125660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Dysregulated Pharmacology of Clinically Relevant
    Andreano KJ; Baker JG; Park S; Safi R; Artham S; Oesterreich S; Jeselsohn R; Brown M; Sammons S; Wardell SE; Chang CY; Norris JD; McDonnell DP
    Mol Cancer Ther; 2020 Jul; 19(7):1395-1405. PubMed ID: 32381587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical relevance of ESR1 circulating mutations detection in hormone receptor positive metastatic breast cancer].
    Clatot F; Perdrix A; Sefrioui D; Sarafan-Vasseur N; Di Fiore F
    Bull Cancer; 2018 Jan; 105(1):46-54. PubMed ID: 29032804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital.
    Bardia A; Iafrate JA; Sundaresan T; Younger J; Nardi V
    Oncologist; 2016 Sep; 21(9):1035-40. PubMed ID: 27551012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer.
    Clatot F; Perdrix A; Beaussire L; Lequesne J; Lévy C; Emile G; Bubenheim M; Lacaille S; Calbrix C; Augusto L; Guillemet C; Alexandru C; Fontanilles M; Sefrioui D; Burel L; Guénot S; Richard D; Sarafan-Vasseur N; Di Fiore F
    Breast Cancer Res; 2020 May; 22(1):56. PubMed ID: 32466779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer.
    Sefrioui D; Perdrix A; Sarafan-Vasseur N; Dolfus C; Dujon A; Picquenot JM; Delacour J; Cornic M; Bohers E; Leheurteur M; Rigal O; Tennevet I; Thery JC; Alexandru C; Guillemet C; Moldovan C; Veyret C; Frebourg T; Di Fiore F; Clatot F
    Int J Cancer; 2015 Nov; 137(10):2513-9. PubMed ID: 25994408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-positive Breast Cancer.
    Goldberg J; Qiao N; Guerriero JL; Gross B; Meneksedag Y; Lu YF; Philips AV; Rahman T; Meric-Bernstam F; Roszik J; Chen K; Jeselsohn R; Tolaney SM; Peoples GE; Alatrash G; Mittendorf EA
    Cancer Res Commun; 2024 Feb; 4(2):496-504. PubMed ID: 38335301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
    Zundelevich A; Dadiani M; Kahana-Edwin S; Itay A; Sella T; Gadot M; Cesarkas K; Farage-Barhom S; Saar EG; Eyal E; Kol N; Pavlovski A; Balint-Lahat N; Dick-Necula D; Barshack I; Kaufman B; Gal-Yam EN
    Breast Cancer Res; 2020 Feb; 22(1):16. PubMed ID: 32014063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activating Mutations of ESR1, BRCA1 and CYP19 Aromatase Genes Confer Tumor Response in Breast Cancers Treated with Antiestrogens.
    Suba Z
    Recent Pat Anticancer Drug Discov; 2017; 12(2):136-147. PubMed ID: 28245776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.